Thanks Mozz.
A few interesting points regarding Lorecivivint.
Failed primary end point phase 2a
Met primary end point phase 2b
Results from phase 3 trial due late 2021, although
this doesn’t make a lot of sense, as trial completion
is planned for 2024 according to Biosplice.
It seems single injection every 52 weeks is the
preferred time span of treatment.
Certainly one to keep an eye on as DMOAD
action appears likely.
MOZZ Research - First Half 2021, page-52
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.005(2.00%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 26.0¢ | 25.0¢ | $33.62K | 131.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 47583 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.5¢ | 24365 | 1 |
View Market Depth
| Last trade - 10.55am 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
25.5¢ |
Change
0.005 ( 1.84 %) |
||||
| Open | High | Low | Volume | ||
| 25.5¢ | 26.0¢ | 25.0¢ | 32507 | ||
| Last updated 10.55am 04/06/2024 ? | |||||
| PAR (ASX) Chart |